Related Experiment Video
Updated: Aug 16, 2025

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
Developing a Novel Immune-Related Seven-Gene Signature and Immune Infiltration Pattern in Patients with COVID-19 and
Yajuan Fu1,2, Juan Zhang1,2,3, Lingbo Xu1,2,3
1National Health Commission Key Laboratory of Metabolic Cardiovascular Diseases Research, Ningxia Medical University, Yinchuan 750004, China.
Insights
Cardiovascular disease (CVD) and COVID-19 share common immune responses and gene signatures. Researchers identified seven key immune-related genes and potential therapeutic targets for better clinical management of these interconnected conditions.
Area of Science:
- Genomics
- Immunology
- Cardiovascular Medicine
Background:
- Patients with pre-existing cardiovascular disease (CVD) are at higher risk for severe COVID-19.
- COVID-19 can lead to long-term cardiovascular complications.
- Understanding shared pathogenic mechanisms and immune signatures is crucial for effective clinical management.
Purpose of the Study:
- To identify common biological molecules and immune signatures linking CVD and COVID-19.
- To discover potential therapeutic targets for managing both conditions.
Main Methods:
- Utilized gene expression profiles from the GEO database for CVD and COVID-19.
- Applied Limma R package and Weighted Gene Co-expression Network Analysis (WGCNA) to identify common differentially expressed genes (DEGs).
- Performed functional enrichment, protein-protein interaction network analysis, and identified hub immune-related genes (HIRGs).
Main Results:
- Identified 57 common DEGs as a shared transcriptional signature.
- Screened 12 hub genes and seven HIRGs (C5AR1, MMP9, CYBB, FPR2, CSF1R, TLR2, TLR4) correlated with macrophages and neutrophils.
- Discovered nine small molecular agents (SMAs) as potential therapeutic drugs.
- Confirmed HIRGs' role in inflammatory pathways (Il2 stat5, Tnfa via nfκb) and their discriminatory capacity.
Conclusions:
- Established a co-expression network for CVD and COVID-19.
- Identified a novel seven-gene immune signature as potential therapeutic targets.
- Provided new insights into pathogenic mechanisms and clinical management strategies for CVD and COVID-19.
Background:
patients with pre-existence of cardiovascular disease (CVD) are vulnerable to coronavirus disease 2019 (COVID-19), and COVID-19 will cause long-term burden of CVD. However, the common pathogenic mechanisms are not fully elucidated. More detailed knowledge of linking biological molecules and the role of immune signature would allow more valuable and specific clinical management.
Methods:
the gene expression profiles of CVD and COVID-19 were retrieved from the GEO database. Common differentially expressed genes (DEGs) were screened with the Limma R package and the WGCNA algorithm, and then functional enrichment analysis, protein-protein interaction network, hub genes, and small therapeutic molecules analyses were performed. The hub immune-related genes (HIRGs) were intersected, and their associations with immune cells, expressional correlation, evaluated performance, and potential signal pathways were further investigated.
Results:
In total, 57 common DEGs were identified as a shared transcriptional signature between CVD and COVID-19, and 12 hub genes were screened using five topological algorithms. There are common altered immune responses in the response of these two diseases, and seven HIRGs, including C5AR1, MMP9, CYBB, FPR2, CSF1R, TLR2, and TLR4, were identified, with positive correlation to altered macrophages and neutrophils. Nine small molecular agents (SMAs) were detected as promising therapeutic drugs. These seven HIRGs mainly participated in the inflammatory immune response through activation of Il2 stat5 signaling and Tnfa signaling via nfκb pathways, and ROC curves confirmed their good discriminatory capacity in the two diseases.
Conclusions:
this study established the co-expression network and identified a new immune-related seven-gene signature as therapeutic targets, which may provide new insights into pathogenic mechanisms and novel clinical management strategies.
More Related Videos
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
12:50Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Published on: September 15, 2017
Related Concept Videos
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Myocarditis II: Clinical Features and Diagnostic Tests
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Myocarditis I: Introduction